W
Werner J. Heinz
Researcher at University of Würzburg
Publications - 102
Citations - 6679
Werner J. Heinz is an academic researcher from University of Würzburg. The author has contributed to research in topics: Posaconazole & Voriconazole. The author has an hindex of 38, co-authored 100 publications receiving 5477 citations.
Papers
More filters
Journal ArticleDOI
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
Andrew J. Ullmann,José María Aguado,S. Arikan-Akdagli,David W. Denning,Andreas H. Groll,Katrien Lagrou,Cornelia Lass-Flörl,Russell E. Lewis,Patricia Muñoz,Paul E. Verweij,Adilia Warris,Florence Ader,Florence Ader,Murat Akova,Maiken Cavling Arendrup,Rosemary Ann Barnes,Catherine Beigelman-Aubry,Catherine Beigelman-Aubry,Stijn Blot,Stijn Blot,Stijn Blot,Emilio Bouza,Roger J. M. Brüggemann,Dieter Buchheidt,Jacques Cadranel,Jacques Cadranel,Elio Castagnola,Arunaloke Chakrabarti,Manuel Cuenca-Estrella,George Dimopoulos,George Dimopoulos,Jesús Fortún,Jean-Pierre Gangneux,Jorge Garbino,Werner J. Heinz,Raoul Herbrecht,Claus Peter Heussel,Christopher C. Kibbler,Nikolay Klimko,Bart Jan Kullberg,Christoph Lange,Thomas Lehrnbecher,Jürgen Löffler,Olivier Lortholary,J Maertens,O. Marchetti,Jacques F. Meis,Livio Pagano,Patricia Ribaud,Malcolm Richardson,Emmanuel Roilides,Markus Ruhnke,Maurizio Sanguinetti,Donald C. Sheppard,János Sinkó,Anna Skiada,Maria J G T Vehreschild,Claudio Viscoli,Oliver A. Cornely +58 more
TL;DR: Treatment duration for aspergillosis is strongly recommended based on clinical improvement, degree of immunosuppression and response on imaging, and in refractory disease, where a personalized approach considering reversal of predisposing factors, switching drug class and surgical intervention is also strongly recommended.
Journal ArticleDOI
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
Johan Maertens,Issam I Raad,Kieren A. Marr,Thomas F. Patterson,Dimitrios P. Kontoyiannis,Oliver A. Cornely,Eric J. Bow,Galia Rahav,Dionysios Neofytos,Mickael Aoun,John W. Baddley,Michael Giladi,Werner J. Heinz,Raoul Herbrecht,William W. Hope,Meinolf Karthaus,Dong-Gun Lee,Olivier Lortholary,Vicki A. Morrison,Ilana Oren,Dominik Selleslag,Shmuel Shoham,George Richard Thompson,Misun Lee,Rochelle Maher,Anne Schmitt-Hoffmann,Bernhardt Zeiher,Andrew J. Ullmann +27 more
TL;DR: The results support the use of isavuconazole for the primary treatment of patients with invasive mould disease and non-inferiority was shown.
Journal ArticleDOI
Isavuconazole Treatment for Mucormycosis: A Single-Arm Open-Label Trial and Case-Control Analysis
Francisco M. Marty,Luis Ostrosky-Zeichner,Oliver A. Cornely,Kathleen M. Mullane,John R. Perfect,George Richard Thompson,George J Alangaden,Janice M. Brown,David N. Fredricks,Werner J. Heinz,Raoul Herbrecht,Nikolai Klimko,Galina Klyasova,Johan Maertens,Sameer R. Melinkeri,Ilana Oren,Peter G. Pappas,Zdeněk Ráčil,Galia Rahav,Rodrigo Ribeiro dos Santos,Stefan Schwartz,Jörg Janne Vehreschild,Jo Anne H. Young,Ploenchan Chetchotisakd,Sutep Jaruratanasirikul,Souha S. Kanj,Marc Engelhardt,Achim Kaufhold,Masanori Ito,Misun Lee,Carolyn Sasse,Rochelle Maher,Bernhardt Zeiher,Maria J G T Vehreschild +33 more
TL;DR: Isavuconazole showed activity against mucormycosis with efficacy similar to amphotericin B, and can be used for treatment of mucormYcosis and is well tolerated.
Journal ArticleDOI
European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 Update
J Maertens,Oscar Marchetti,Raoul Herbrecht,Oliver A. Cornely,Ursula Flückiger,Pascale Frere,Bertrand Gachot,Werner J. Heinz,Cornelia Lass-Flörl,Patricia Ribaud,A Thiebaut,Catherine Cordonnier +11 more
TL;DR: The goal of this paper is to summarize the new proposals from ECIL 3, based on the results of studies published after the ECIL 2 meeting, and the prophylactic recommendations for hematopoietic stem cell transplant recipients were formulated differently.
Journal ArticleDOI
Combination antifungal therapy for invasive aspergillosis a randomized trial
Kieren A. Marr,Haran T. Schlamm,Raoul Herbrecht,Scott T. Rottinghaus,Eric J. Bow,Oliver A. Cornely,Werner J. Heinz,Shyla Jagannatha,Liang Piu Koh,Dimitrios P. Kontoyiannis,Dong-Gun Lee,Marcio Nucci,Peter G. Pappas,Monica A. Slavin,Flavio Queiroz-Telles,Dominik Selleslag,Thomas J. Walsh,John R. Wingard,Johan Maertens +18 more
TL;DR: The primary end point of this study was all-cause mortality at 6 weeks, rather than the composite global response, which had been shown to most closely approximate the deaths attributable to IA rather than deaths caused by underlying disease.